Leadyond Capital
Leadyond Capital, established in 2007, is a Chinese private equity firm that focuses on mid to late-stage buyout investments. It primarily targets manufacturing and service industries, with a secondary focus on energy, environment, material, healthcare, financial services, and industrial sectors. The firm, now inactive, was known for its professional, patient, and prudent approach, aiming to create new value through specialized services and aligning strategies with its partners.
Top Stages
2 past transactions
HitGen
Series B in 2018
HitGen Inc. is a biotechnology company based in Chengdu, China, specializing in early-stage drug discovery through its innovative platform centered on DNA encoded chemical libraries (DELs). The company develops diverse, drug-like small molecules and macrocycle compounds, contributing to various therapeutic areas including oncology, cardiovascular diseases, inflammation, metabolism, and ophthalmology. HitGen is involved in multiple internal research projects, which are at various stages of development, including Phase I and lead generation. Additionally, the company collaborates with notable partners such as Gilead Sciences, Galapagos NV, Kymera Therapeutics, and Morphic Therapeutic to identify potential small molecule leads, and has a strategic partnership with Oncodesign for advancing new chemical entities. Founded in 2012, HitGen also provides biological reagents and technical consultation services to support drug discovery research.
Yi animation
Series B in 2016
Yi Animation is a domestic company that specializes in original animation production, distribution, authorization, derivative industry platforms, and other full-visual IP animation development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.